小峰啓吾 (Keigo Komine) - マイポータル

Retrospective analysis on the clinical outcomes of recombinant human soluble thrombomodulin for disseminated intravascular coagulation syndrome associated with solid tumors.

Ouchi K, Takahashi S, Chikamatsu S, Ito S, Takahashi Y, Kawai S, Okita A, Kasahara Y, Okada Y, Imai H …

International journal of clinical oncology 23(4) 790-798 2018年8月査読有り

Predictive factors for the efficacy of the second taxane treatment in patients with advanced cancer.

Imai H, Saijo K, Komine K, Kawamura Y, Hiraide S, Umegaki S, Okada Y, Ohuchi K, Sato Y, Takahashi M …

Cancer management and research 10 3629-3636 2018年査読有り

Efficacy and safety of gemcitabine plus docetaxel in Japanese patients with unresectable or recurrent bone and soft tissue sarcoma: Results from a single-institutional analysis

Masanobu Takahashi, Keigo Komine, Hiroo Imai, Yoshinari Okada, Ken Saijo, Masahiro Takahashi, Hidekazu Shirota, Hisatsugu Ohori, Shin Takahashi, Natsuko Chiba …

PLOS ONE 12(5) e0176972 2017年5月査読有り

CpG island methylator phenotype is associated with the efficacy of sequential oxaliplatin- and irinotecan-based chemotherapy and EGFR-related gene mutation in Japanese patients with metastatic colorectal cancer

Xiaofei Zhang, Hideki Shimodaira, Hiroshi Soeda, Keigo Komine, Hidekazu Takahashi, Kota Ouchi, Masahiro Inoue, Masanobu Takahashi, Shin Takahashi, Chikashi Ishioka

International Journal of Clinical Oncology 21(6) 1091-1101 2016年12月査読有り

A Curcumin Analog, GO-Y078, Effectively Inhibits Angiogenesis through Actin Disorganization

Shunsuke Sugiyama, Yuki Yoshino, Sei Kuriyama, Masahiro Inoue, Keigo Komine, Kazunori Otsuka, Aki Kohyama, Hiroyuki Yamakoshi, Chikashi Ishioka, Masamitsu Tanaka …

ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY 16(5) 633-647 2016年査読有り

Attainment of a Long-term Favorable Outcome by Sunitinib Treatment for Pancreatic Neuroendocrine Tumor and Renal Cell Carcinoma Associated with von Hippel-Lindau Disease

Akihiro Kobayashi, Masanobu Takahashi, Hiroo Imai, Shoko Akiyama, Shunsuke Sugiyama, Keigo Komine, Ken Saijo, Masahiro Takahashi, Shin Takahashi, Hidekazu Shirota …

INTERNAL MEDICINE 55(6) 629-634 2016年査読有り

Functional Complementation Assay for 47 MUTYH Variants in a MutY-Disrupted Escherichia Coli Strain

Keigo Komine, Hideki Shimodaira, Masashi Takao, Hiroshi Soeda, Xiaofei Zhang, Masanobu Takahashi, Chikashi Ishioka

HUMAN MUTATION 36(7) 704-711 2015年7月査読有り

[Points of management for elderly patients in chemotherapy].

Komine K, Ishioka C

Nihon rinsho. Japanese journal of clinical medicine 73 Suppl 2 51-56 2015年2月査読有り

Efficacy and Safety of Carboplatin and Etoposide Combination Chemotherapy for Extrapulmonary Neuroendocrine Carcinoma: A Retrospective Case Series

Hiroo Imai, Hidekazu Shirota, Akira Okita, Keigo Komine, Ken Saijo, Masahiro Takahashi, Shin Takahashi, Masanobu Takahashi, Hideki Shimodaira, Chikashi Ishioka

CHEMOTHERAPY 61(3) 111-116 2015年査読有り

Efficacy and Safety Assessment of Paclitaxel in Patients with Docetaxel-Resistant Esophageal Squamous Cell Carcinoma

Hiroo Imai, Keigo Komine, Shin Takahashi, Ken Saijo, Yoshinari Okada, Akihiro Kobayashi, Akira Okita, Sonoko Chikamatsu, Yuki Kasahara, Masahiro Takahashi …

CHEMOTHERAPY 61(5) 262-268 2015年査読有り

Utility of Measuring Circulating Tumor Cell Counts to Assess the Efficacy of Treatment for Carcinomas of Unknown Primary Origin

Keigo Komine, Masahiro Inoue, Kazunori Otsuka, Koji Fukuda, Hiroshi Nanjo, Hiroyuki Shibata

ANTICANCER RESEARCH 34(6) 3165-3168 2014年6月査読有り

KRAS mutation in patients with metastatic colorectal cancer does not preclude benefit from oxaliplatin-or irinotecan-based treatment.

Soeda H, Shimodaira H, Watanabe M, Suzuki T, Gamo M, Takahashi M, Komine K, Kato S, Ishioka C

Molecular and clinical oncology 2(3) 356-362 2014年5月査読有り

Preliminary estimation of the prevalence of chemotherapy-induced dysgeusia in Japanese patients with cancer

Hiroo Imai, Hiroshi Soeda, Keigo Komine, Kazunori Otsuka, Hiroyuki Shibata

BMC PALLIATIVE CARE 12(1) 38 2013年10月査読有り

Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer

Hiroshi Soeda, Hideki Shimodaira, Mika Watanabe, Takao Suzuki, Makio Gamoh, Takahiro Mori, Keigo Komine, Noriyuki Iwama, Shunsuke Kato, Chikashi Ishioka

International Journal of Clinical Oncology 18(4) 670-677 2013年8月査読有り

Practical Utility of Circulating Tumour Cells as Biomarkers in Cancer Chemotherapy for Advanced Colorectal Cancer

Kazunori Otsuka, Hiroo Imai, Hiroshi Soeda, Keigo Komine, Chikashi Ishioka, Hiroyuki Shibata

ANTICANCER RESEARCH 33(2) 625-629 2013年2月査読有り

Antibody-dependent cellular cytotoxicity in the immunotherapeutic mechanisms of anti-EGFR monoclonal antibody

Hideki Shimodaira, Keigo Komine, Hiroshi Soeda, Chikashi Ishioka

Japanese Journal of Cancer and Chemotherapy 37(5) 795-798 2010年査読有り

Status of components in EGFR-related signal transduction as predictive markers for anti-EGFR antibody therapy in colorectal cancer treatment

Hideki Shimodaira, Hiroshi Soeda, Keigo Komine, Chikashi Ishioka

Japanese Journal of Cancer and Chemotherapy 36(7) 1063-1066 2009年査読有り

小峰啓吾

基本情報

論文

メニュー